Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press6510.17650/1994-4098-2013-0-3-4-97-100GYNECOLOGY. DIAGNOSISГИНЕКОЛОГИЯ. ДИАГНОСТИКАUltrasonic, hysteroscopic and histological evaluation of the endometrium in women receiving tamoxifen for breast cancerУльтразвуковая, гистероскопическая и гистологическая оценка эндометрия у женщин, получающих тамоксифен по поводу рака молочной железыMelnikovaN. S.МельниковаН. С.
Russian Federation
mel-ns@yandex.ruKozlovaO. V.КозловаО. В.
Russian Federation
LarionovO. V.ЛарионовО. В.
Russian Federation
Clinical Hospital of the Presidential Administration of the Russian Federation, MoscowФГБУ «Клиническая больница» Управления делами Президента РФ, Москва220920133-49710022072014220720142013https://ojrs.abvpress.ru/ojrs/article/view/65

The article investigates the influence of the tamoxifen on the endometrium of patients receiving antiestrogen therapy in treatment of breast cancer. Studied by ultrasound, and hysteroscopic endometrial pathological characteristics during treatment with tamoxifen to optimize the tactics of this group of patients.

Статья посвящена исследованию влияния препарата тамоксифен на эндометрий пациенток, получающих терапию анти- эстрогенами в комплексном лечении рака молочной железы. Изучены ультразвуковые, гистероскопические и патоморфологи- ческие характеристики эндометрия на фоне применения тамоксифена с целью оптимизации тактики ведения данной группы пациенток.

endometrial pathologytamoxifenbreast cancerultrasoundhysteroscopyвнутриматочная патологиятамоксифенрак молочной железыультразвуковое исследованиегистероскопия1. Machado F., Rodriguez J.R., Leon J.P. et al. Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature. Eur J Gynaecol Oncol 2005;26:257–65.Machado F., Rodriguez J.R., Leon J.P. et al. Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature. Eur J Gynaecol Oncol 2005;26:257–65.2. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004;94:256–66.Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004;94:256–66.3. Чекалова М.А., Махова Е.Е., Шабанов М.А. и др. Ультразвуковой мониторинг состояния эндометрия у больных раком молочной железы. Сиб онкол журн 2007. Приложение. С. 97–109.Чекалова М.А., Махова Е.Е., Шабанов М.А. и др. Ультразвуковой мониторинг состояния эндометрия у больных раком молочной железы. Сиб онкол журн 2007. Приложение. С. 97–109.4. Тарутинов В.И. Фарестон (торемифен): многогранность эффекта при предопухолевой и опухолевой патологии. Онкология 2009;11(1):65–70.Тарутинов В.И. Фарестон (торемифен): многогранность эффекта при предопухолевой и опухолевой патологии. Онкология 2009;11(1):65–70.5. Bertelli G., Hall E., Ireland E. et al. Long- term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES) – a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen. Ann Oncol 2010 March;21(3):498–505.Bertelli G., Hall E., Ireland E. et al. Long- term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES) – a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen. Ann Oncol 2010 March;21(3):498–505.6. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–717.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–717.7. Neven P., Vergote I. Should tamoxifen users be screened for endometrial lesions? Lancet 1998;351:155–7.Neven P., Vergote I. Should tamoxifen users be screened for endometrial lesions? Lancet 1998;351:155–7.8. Стенина М.Б. Гормонотерапия диссеминированного рака молочной железы. Практич онкол 2000;2:12–8.Стенина М.Б. Гормонотерапия диссеминированного рака молочной железы. Практич онкол 2000;2:12–8.9. Smith-Bindman R., Kerlikowske K., Feldstein V.A. et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 1998;280:1510–7.Smith-Bindman R., Kerlikowske K., Feldstein V.A. et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 1998;280:1510–7.10. Salazar E.L., Paredes A., Calzada L. Endometrial thickness of postmenopausal breast cancer patients treated with tamoxifen. Gynecol Endocrinol 2005;21:312–6.Salazar E.L., Paredes A., Calzada L. Endometrial thickness of postmenopausal breast cancer patients treated with tamoxifen. Gynecol Endocrinol 2005;21:312–6.11. Gardner F.J., Konje J.C., Brown L. et al. Uterine surveillance of asymptomatic postmenopausal women taking tamoxifen. Climacteric 1998;1:180–7.Gardner F.J., Konje J.C., Brown L. et al. Uterine surveillance of asymptomatic postmenopausal women taking tamoxifen. Climacteric 1998;1:180–7.12. Love C.D., Muir B.B., Scrimgeour J.B. et al. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999;17:2050–4.Love C.D., Muir B.B., Scrimgeour J.B. et al. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999;17:2050–4.13. Mourits M.J., Van der Zee A.G., Willemse P.H. et al. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. Gynecol Oncol 1999;73:21–6.Mourits M.J., Van der Zee A.G., Willemse P.H. et al. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. Gynecol Oncol 1999;73:21–6.14. Tesoro M.R., Borgida A.F., MacLaurin N.A. et al. Transvaginal endometrial sonography in postmenopausal women taking tamoxifen. Obstet Gynecol 1999;93:363–6.Tesoro M.R., Borgida A.F., MacLaurin N.A. et al. Transvaginal endometrial sonography in postmenopausal women taking tamoxifen. Obstet Gynecol 1999;93:363–6.15. Bertelli G., Venturini M., Del Mastro L. et al. Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat 1998;47:41–6.Bertelli G., Venturini M., Del Mastro L. et al. Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat 1998;47:41–6.16. Gerber B., Krause A., Muller H. et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: A prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000;18:3464–70.Gerber B., Krause A., Muller H. et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: A prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000;18:3464–70.17. Love C.D., Dixon J.M. Thickened endometrium caused by tamoxifen returns to normal following tamoxifen cessation. Breast. 2000;9:156–7.Love C.D., Dixon J.M. Thickened endometrium caused by tamoxifen returns to normal following tamoxifen cessation. Breast. 2000;9:156–7.18. Menada M.V., Papadia A., Lorenzi P. et al. Modification of ultrasonographically measured endometrial thickness after discontinuation of adjuvant therapy with tamoxifen in postmenopausal breast cancer patients. Eur J Gynaecol Oncol 2004;25:321–3.Menada M.V., Papadia A., Lorenzi P. et al. Modification of ultrasonographically measured endometrial thickness after discontinuation of adjuvant therapy with tamoxifen in postmenopausal breast cancer patients. Eur J Gynaecol Oncol 2004;25:321–3.19. Cohen I., Beyth Y., Azaria R. et al. Ultrasonographic measurement of endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients. BJOG 2000;107:1083–7.Cohen I., Beyth Y., Azaria R. et al. Ultrasonographic measurement of endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients. BJOG 2000;107:1083–7.20. Kazerooni T., Ghaffarpasand F., Mosalaei A., Kazerooni Y. The value of transvaginal ultrasonography in the endometrial evaluation of breast cancer patients using tamoxifen. Med Princ Pract 2010;19(3):222–7.Kazerooni T., Ghaffarpasand F., Mosalaei A., Kazerooni Y. The value of transvaginal ultrasonography in the endometrial evaluation of breast cancer patients using tamoxifen. Med Princ Pract 2010;19(3):222–7.21. Bornstein J., Auslender R., Pascal B. et al. Diagnostic pitfalls of ultrasonographic uterine screening in women treated with tamoxifen. J Reprod Med 1994;39:674–8.Bornstein J., Auslender R., Pascal B. et al. Diagnostic pitfalls of ultrasonographic uterine screening in women treated with tamoxifen. J Reprod Med 1994;39:674–8.22. Garuti G., Cellani F., Colonnelli M. et al. Hysteroscopically targeted biopsies compared with blind samplings in endometrial assessment of menopausal women taking tamoxifen for breast cancer. J Am Assoc Gynecol Laparosc 2004 Feb;11(1):62–7.Garuti G., Cellani F., Colonnelli M. et al. Hysteroscopically targeted biopsies compared with blind samplings in endometrial assessment of menopausal women taking tamoxifen for breast cancer. J Am Assoc Gynecol Laparosc 2004 Feb;11(1):62–7.23. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion. No. 336: tamoxifen and uterine cancer. Obstet Gynecol 2006;107:1475–8.American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion. No. 336: tamoxifen and uterine cancer. Obstet Gynecol 2006;107:1475–8.24. Althuis M.D., Sexton M., Langenberg P. et al. Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors: a community based study. Cancer 2000;89:800–10.Althuis M.D., Sexton M., Langenberg P. et al. Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors: a community based study. Cancer 2000;89:800–10.